SGLT2 inhibitors may enable continuation of RAAS inhibitors for hypertension treatment, which is linked with better kidney and cardiovascular outcomes.

Order expected to affect specific medications covered under Medicare that are administered in a health care setting.

(HealthDay News) — For female patients with multiple sclerosis (MS), transcutaneous posterior tibial nerve stimulation (TPTNS) and repetitive transcranial magnetic stimulation (rTMS) are comparable ...

Illness severity, comorbidities, and prior exposure to antibiotics associated with hospital-onset antimicrobial resistant infections.

Patients with diabetic macular edema treated with intravitreal aflibercept have a significantly higher risk of adverse renal events compared with those treated with ranibizumab.

(HealthDay News) — The number of kidney transplants performed annually in the United States has increased steadily, but with decreasing allocation efficiency, according to a study published online in ...

Sustainable development efforts such as lowering out-of-pocket health expenses can reduce future prevalence of AMR by 5.1 percent.

Four hours without power increases odds of pediatric CO poisoning ED visit for all-scale, large-scale power outages.

(HealthDay News) — The U.S. Department of Health and Human Services and the National Institutes of Health announced a new initiative called “Generation Gold Standard” to develop next-generation, ...

Investigators assessed the frequency of lupus flares in patients with kidney failure undergoing dialysis or with a kidney transplant.

AstraZeneca has made the decision to end the CAPItello-280 trial evaluating capivasertib in patients with metastatic castration-resistant prostate cancer.

SGLT-2 inhibitor use vs DPP-4 inhibitor use was associated with lower incidence of epilepsy among patients with type 2 diabetes.